In neuroblastoma, two BDP1 variants were identified to be associated with poor clinical outcomes36 and recently, BDP1 expression has been correlated with clinical outcomes in non‐Hodgkin lymphoma (NHL)35 and breast cancer.34 Here, BDP1 is linked to non-Hodgkin lymphoma.